Latest Regulatory Compliance News

NH3 Clean Energy has received multiple engineering proposals for the Front End Engineering and Design (FEED) of its WAH2 clean ammonia project and commenced a detailed flora survey, marking significant progress toward its Final Investment Decision by year-end.

Star Minerals has obtained the crucial Native Vegetation Clearing Permit, completing all regulatory approvals to commence mining at the Tumblegum South Gold Project in Western Australia.

Native Mineral Resources has reported impressive shallow high-grade gold intercepts at its Podosky deposit, reinforcing plans to commence mining by April 2026. The results bolster confidence in the deposit’s open-pit potential and support ongoing development at the Ravenswood Gold Project.

BluGlass Limited has confirmed it is finalising a significant customer order following a sharp rise in its share price and trading volumes, with a formal announcement expected on 9 March 2026.

Terra Critical Minerals has clarified that its recent share price jump is tied to soaring tungsten prices and its acquisition of a key US tungsten project. The company confirms compliance with ASX disclosure rules amid heightened market interest.

Celsius Resources' subsidiary has formally notified its partner of plans to relinquish a 60% stake in Makilala Mining Company, with regulatory compliance and shareholder engagement underway.

Pearl Gull Iron Limited’s shares have been suspended from ASX trading following the sale of its main asset, the Cockatoo Island Project, as the company works to meet compliance requirements.

Beetaloo Energy has responded to ASX concerns over a delayed disclosure of a director's change in interest, attributing it to an administrative oversight and pledging enhanced compliance measures.

Little Green Pharma Ltd (ASX: LGP) has proposed a full acquisition of Cannatrek Ltd via a scheme of arrangement, creating a vertically integrated medicinal cannabis group with pro forma FY26 revenues exceeding AUD 100 million. The scheme, supported by an independent expert, offers liquidity and strategic growth opportunities amid regulatory and market risks.

Magellan Financial Group has applied for quotation of over 15 million new shares following a recent transaction, alongside announcing a $20 million Share Purchase Plan targeting further capital raising.

LTR Pharma has finalised recruitment for its Phase II clinical trial of SPONTAN, a rapid-acting intranasal spray for erectile dysfunction, with initial results expected in the second quarter of 2026.

Bapcor Limited has initiated a fully underwritten $200 million equity raising at $0.60 per share, aiming to reduce debt and support a strategic turnaround under new leadership. The retail entitlement offer opened on 5 March and closes on 19 March 2026.